Host-pathogen interactions in emerging and re-emerging infectious diseases: A genomic perspective of tuberculosis, malaria, human immunodeficiency virus infection, hepatitis B, and cholera

Annual Review of Public Health

Volumn 21, Issue , 2000, Pages 15-46

  McNicholl, Janet M ^a   Downer, Marie V ^a   Udhayakumar, Venkatachalam ^b   Alper, Chester A ^d   Swerdlow, David L ^c  

^a National Center for HIV STD and TB Prevention   (United States)

^b Div Parasitic Dis Centers Dis C   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^d CENTER FOR BLOOD RESEARCH   (United States)

Author keywords

Gene; Polymorphism; Resistance; Susceptibility; Vaccines

Indexed keywords

CHOLERA; CONFERENCE PAPER; HEPATITIS B; HEPATITIS B VIRUS; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; MALARIA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; TUBERCULOSIS; VIBRIO CHOLERAE;

CHOLERA; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B; HIV INFECTIONS; HUMANS; IMMUNITY, NATURAL; MALARIA; MODELS, STATISTICAL; MORBIDITY; POLYMORPHISM, GENETIC; POPULATION SURVEILLANCE; PUBLIC HEALTH PRACTICE; TUBERCULOSIS; WORLD HEALTH;

EID: 0033942589     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.21.1.15     Document Type: Conference Paper

References (154)

1. 1. Abel L, Dessein AJ. 1998. Genetic epidemiology of infectious diseases in humans: design of population-based studies. Emerg. Infect. Dis. 4:593-603
2. 2. Deleted in proof
3. +-thalassemia protects children against disease caused by other infections as well as malaria. Proc. Natl. Acad. Sci. USA 94:14, 736-41
4. 4. Allison AC. 1954. Protection afforded by sickle cell trait against subtertian malarial infection. Br. Med. J. 1:190
5. 5. Alper CA, Kruskall MS, Marcus-Bagley D, Craven DE, Katz AJ, et al. 1989. Genetic prediction of nonresponse to hepatitis B vaccine. N. Engl. J. Med. 321:708-12
6. 6. Altare F, Durandy A, Lammas D, Emile JF, Lamhamedi S, Le Deist F. 1998. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432-35
7. 7. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, et al. 1998. CCR2-64I allele and genotype associations with delayed AIDS progression in African women. Lancet 351:1632-33
8. 8. Baggiolini M, Moser B. 1997. Blocking chemokine receptors. J. Exp. Med. 186:1189-91
9. 9. Barua D, Paguio AS. 1997. ABO blood groups and cholera. Ann. Hum. Biol. 4:489-92
10. 10. Sehr M, Wilson M, Gill W, Salamon H, Schoolnik G, et al. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520-23
11. 10a. Bellamy R, Hill AVS. 1999. A bi-allelic tetranucleotide repeat in the promoter of the human inducible nitric oxide synthase gene. Clin. Genet. 52:192-93
12. 11. Bellamy R, Kwiatkowski D, Hill A. 1998. Absence of an association between intercellular adhesion molecule 1, complement receptor 1, and interleukin 1 receptor antagonist gene polymorphisms and severe malaria in a West African population. Trans. R. Soc. Trop. Med. Hyg. 92:312-16
13. 12. Bellamy R, Ruwende C, Corrah T, McAdam KPWJ, Thursz M, et al. 1999. Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 179:721-24
14. 13. Bellamy R, Ruwende C, Corrah T, McAdam KPWJ, Whittle HC, Hill AVS. 1998. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N. Engl. J. Med. 338:640-44
15. 14. Bellamy R, Ruwende C, McAdam KPWJ, Thursz M, Sumiya M, et al. 1998. Mannose binding protein deficiency is not associated with malaria, hepatitis B carriage nor tuberculosis in Africans. Q. J. Med. 91:13-18
16. 15. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, et al. 1999. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1:3-19
17. 16. Blackwell CC, James VS, Davidson S, Wyld R, Brettle RP, et al. 1991. Secretor status and heterosexual transmission of HIV. Br. Med. J. 303:825-26
18. 17. Bogardus S, Concato J, Feinstein A. 1999. Clinical epidemiological quality in molecular genetic research: the need for methodological standards. 1999. J. Am. Med. Assoc. 281:1919-26
19. 18. Bothamley G, Beck J, Schreuder G, D'Amaro J, de Vries R, et al. 1989. Association of tuberculosis and M. tuberculosis antibody levels with HLA. J. Infect. Dis. 159:549-55
20. 19. Brahmajothi V, Pitchappan R, Kakkanaiah V, Sashidhar M, Rajaram K, et al. 1991. Association of pulmonary tuberculosis and HLA in South India. Tubercle 72:123-32
21. 20. Carrington M, Nelson G, Martin M, Kissner T, Vlahov D, et al. 1999. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283:1748-52
22. 21. Cattani JA, Gibson FD, Alpers MP, Crane GG. 1987. Hereditary ovalocytosis and reduced susceptibility to malaria in Papua, New Guinea. Trans. R. Soc. Trop. Med. Hyg. 81:705-9
23. 21a. Centers for Disease Control and Prevention. 1990. Protection against viral hepatitis: recommendations of the Immunization Practices Advisory Committee (ACIP). Morbid. Mortal. Wkly. Rep. 39:5-22
24. 22. Centers for Disease Control and Prevention. 1997. Translating advances in human genetics into public health action: a strategic plan. U.S. Dep. Health Hum. Serv., Public Health Serv., Atlanta, GA. http://www.cdc.gov/genetics/Stratpl.html
25. 23. Centers for Disease Control and Prevention. 1998. Preventing emerging infectious diseases: a strategy for the 21st century. U.S. Dep. Health Hum. Serv., Public Health Serv., Atlanta, GA.
26. 24. Chaudhuri A,DasAdhikary CR. 1978. Possible role of blood-group secretory substances in the aetiology of cholera. Trans. R. Soc. Trop. Med. Hyg. 72:664-65
27. 25. Chaudhuri A, De S. 1977. Cholera and blood-groups. Lancet 2:404
28. 26. Chen DF, Kliem V, Endres W, Brunkhorst R, Tillmann HL, et al. 1996. Relationship between human leukocyte antigen determinants and courses of hepatitis B virus infection in Caucasian patients with end-stage renal disease. Scand. J. Gastroenterol. 31:1211-15
29. 27. Clemens JD, Sack DA, Harris JR. 1989. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J. Infect. Dis. 159:770-73
30. 28. Colditz GA, Brewer TF, Berkeley CS, Wilson ME, Burdick E, et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis: meta analysis of the published literature. J. Am. Med. Assoc. 271:698-702
31. 29. Comstock GW. 1978. Tuberculosis in twins: a re-analysis of the Prophit survey. Am. Rev. Respir. Dis. 117:621-24
32. 30. Craven DE, Awdeh ZL, Kunches LM, Yunis EJ, Dienstag JL, et al. 1986. Nonresponsiveness to hepatitis B vaccine in health care workers: results of revaccination and genetic typings. Ann. Intern. Med. 105:356-60
33. 31. Crowle AJ, Ross EJ, May MH. 1987. Inhibition by 1,25 (OH) 2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect. Immun. 55:2945-50
34. 32. Davenport MP, Hill AV. 1996. Reverse immunogenetics: from HLA-disease associations to vaccine candidates. Mol. Med. Today 2:38-45
35. 33. Davis HL. 1999. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt. Sinai J. Med. 66: 84-90
36. 34. de Jong R, Altare F, Haagen IA, Elferink DG, de Boer T, van Breda Vriesman PJC. 1998. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435-38
37. 35. Desombere I, Hauser P, Rossau R, Paradijs J, Leroux-Roels G. 1995. Nonresponders to hepatitis B vaccine can present envelope particles to T lymphocytes. J. Immunol. 154:520-29
38. 36. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B virus infection. N. Engl. J. Med. 333:1657-61
39. 37. Diepolder HM, Jung MC, Keller E, Schraut W, Gerlach JT, et al. 1998. A vigorous virus-specific CD4+ T cell response may contribute to the association of HLA-DR13 with viral clearance in hepatitis B. Clin. Exp. Immunol. 113:244-51
40. 38. Dolin PJ, Raviglione MC, Kochi A. 1994. Global tuberculosis incidence and mortality during 1990-2000. Bull. World Health Organ. 70:213-20
41. 38a. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. 1999. Consensus statement. Global burden of tuberculosis: estimated incidence and mortality by country. WHO Global Surveillance and Monitoring Project. J. Am. Med. Assoc. 282:677-86
42. 39. Egea E, Iglesias A, Salazar M, Morimoto C, Kruskall MS, et al. 1991. The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J. Exp. Med. 173:531-38
43. 40. Ellard GA. 1976. Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther. 19:610-25
44. 41. Evans D. 1993. Genetics factors in drug therapy: clinical and molecular pharmacogenetics. Cambridge, UK: Cambridge Univ. Press. 211 pp.
45. 42. Farmer P, Kim JY. 1998. Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus." Br. Med. J. 317:671-74
46. 43. Fernandez-Reyes D, Craig AG, Kyes SA, Peshu N, Snow RW, et al. 1997. A high frequency African coding polymorphism in the N-terminal domain of ICAM-1 pre-disposing to cerebral malaria. Hum. Mol. Genet. 6:1357-60
47. 44. Flatz G, Pik C, Sundharagiati B. 1964. Malaria and haemoglobin E in Thailand. Lancet 2:385
48. 45. Fontelo P. 1995. Protection against cholera. Science 267:440
49. 46. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. 1994. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266:107-9
50. 47. Ganem D. 1998. Towards a rational therapy for hepatitis B. J. Clin. Invest. 102:867-68
51. 48. Garred P, Madson HO, Balslev U, Hofmann B, Gerstoft J, Svejgaard A. 1997. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannose-binding lectin. Lancet 349:236-40
52. 49. Gayle HD. 1999. Director's forum. CDC NCHSTP News Notes 1:2
53. 50. Genton B, Al-Yaman F, Mgone CS, Alexander N, Paniu MM, et al. 1995. Ovalocytosis and cerebral malaria. Nature 378:564-65
54. 50a. Gjertson DW, Terasaki PL, eds. 1998. HLA 1998. Lenexa, KS: Am. Soc. Histocompat. Immunogenet. 468 pp.
55. 51. Glass RI, Holmgren J, Haley CE, Khan MR, Svennerholm AM, et al. 1985. Pre-disposition for cholera of individuals with O blood group: possible evolutionary significance. Am. J. Epidemiol. 121:791-96
56. 52. Goldfeld AE, Delgado JC, Thim S, Bozon MV, Uglialoro AM, et al. 1998. Association of an HLA-DQ allele with clinical tuberculosis. J. Am. Med. Assoc. 279:226-28
57. 52a. Greenwood B, Marsh K, Snow R. 1991. Why do some African children develop severe malaria? Parasitol. Today 7:277-2 81
58. 53. Grotto I, Mandel Y, Ephros M, Ashkenazi I, Shemer J. 1998. Major adverse reactions to yeast-derived hepatitis B vaccines - a review. Vaccine 16:329-34
59. 54. Haber P, Mootrey G, Euler G, Singleton J, McNicholl J. 1999. Rheumatoid arthritis following hepatitis B vaccinations in adults. Proc. Intersci. Conf. Antimicrob. Agents Chemother., 39th, San Francisco, p. 374. Washington, DC: Am. Soc. Microbio l.
60. 55. Haldane JBS. 1949. The rate of mutations of human genes. Hereditas 35(Suppl.):2 67
61. 55a. Halsey NA, Duclos P, Van Damme P, Margolis H, The Viral Hepatitis Prevention Board. 1999. Hepatitis B vaccine and central nervous system demyelinating diseases. Pediatr. Infect. Dis. J. 18:23-24
62. 56. Hill AVS. 1998. The immunogenetics of human infectious diseases. Annu. Rev. Immunol. 16:593-6 17
63. 57. Hill AVS, Allsopp CEM, Kwiatkowski D, Anstey NM, Twumasi P, et al. 1991. Common West African HLA antigens are associated with protection from severe malaria. Nature 352:595-6 00
64. 58. Hill AVS, Elvin J, Willis AC, Aidoo M, Allsopp CEM, et al. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360:434-39
65. 59. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis L, et al. 1999. Mannose-binding protein B allele confers protection against tuberculous meningitis. Pediatr. Res. 45:459-64
66. 60. Hohler T, Gerken G, Notghi A, Lubjuhn R, Taheri H, et al. 1997. HLA-DRB1*1301 and *1302 protect against chronic hepatitis B. J. Hepatol. 26:503 -7
67. 61. Hohler TM, Wunschel M, Gerken G, Schneider PM, Meyer Zum Buschenfelde KH, Rittner C. 1998. No association between mannose-binding lectin alleles and susceptibility to chronic hepatitis B virus infection in German patients. Exp. Clin. Immunogenet. 15:130-33
68. 62. Honkoop P, de Man RA, Zondervan PE, Schalm SW. 1997. Histological improvement in patients with chronic hepatitis B infection treated with lamivudine. Liver 17:103 -6
69. 63. Honkoop P, Niesters HGM, de Man RAM, Osterhaus ADME, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. Hepatology 26:1393-95
70. 64. Huang Y, Paxton WA, Wolinsky SM, Neumann AU, Zhang L, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat. Med. 2:1240-43
71. 65. Ioannidis JPA, O'Brien TR, Rosenberg PS, Contopoulos-Ioannidis DG, Goedert JJ. 1998. Genetic effects on HIV disease progression. Nat. Med. 4:536
72. 66. Jouanguy E, Lamhamedi-Cherradi S, Lammas D, Dorman S, Fondaneche M, et al. 1999. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 21:370-78
73. 67. Kaslow R. 1997. Host genes and HIV infection: implications and applications. Emerg. Infect. Dis. 3:401-2
74. 68. Kaslow RA, Koup R, Zimmerman P, Dean M, Naik E, et al. 1997. HLA scoring profile (HSP) and CCR5 deletion heterozygosity as predictors of AIDS in seroconverters. In Proc. Conf. Retroviruses Opportunistic Infect., 4th, Am. Soc. Microbiol., Washington, D.C., p. 69
75. 69. Kaslow RA, McNicholl JM. 1999. Genetic determinants of HIV infection and its manifestations. Proc. Assoc. Am. Phys. 111:299-307
76. 70. Khomenko AG, Litvinov VI, Chukanova VP, Pospelov LE. 1990. Tuberculosis in patients with various HLA phenotypes. Tubercle 71:187-92
77. 71. Khoo SH, Pepper L, Snowden N, Hajeer AH, Vallely P, et al. Tumor necrosis factor c2 microsatellite allele is associated with the rate of HIV disease progression. AIDS 11:423-28
78. 72. Khoury MJ, Dorman JS. 1998. Editorial: the human genome epidemiology network. Am. J. Epidemiol. 148:1-3
79. 73. Knight J, Udalova I, Hill A, Greenwood B, Peshu N, et al. 1999. A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nat. Genet. 22:145-50
80. 74. Knuchel MC, Spira TJ, Neumann AU, Xiao L, Rudolph DL, et al. 1998. Analysis of a biallelic polymorphism in the tumor necrosis factor a promoter and HIV type 1 disease progression. AIDS Res. Hum. Retroviruses 14:305-9
81. 75. Kun JFJ, Mordmuller B, Bertrand L, Lehman LG, Luckner D, Kremsner PG. 1998. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 351:265-66
82. 76. Levne MM, Nalin DR, Rennels MB. 1979. Genetic susceptibility to cholera. Ann. Hum. Biol. 6:369-74
83. 77. Li K, Leung NW, Poon AS, Wong KC, Chan TH, Lai KN. 1995. Molecular genetics of major histocompatibility complex class II genes in hepatocellular carcinoma. Dig. Dis. Sci. 40:1542-46
84. 77a. Lipscombe RJ, Sumiya M, Hill AV, Lau YL, Levinsky RJ, et al. 1992. High frequencies in African and non-African populations of independent mutations in the mannose binding protein gene. Hum. Mol. Genet. 1:709-15
85. 78. Liu H, Chao D, Nakayama E, Taguchi H, Goto M, et al. 1999. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc. Natl. Acad. Sci. USA 96:4581-85
86. 79. Luzzatto L, Usanga EA, Reddy S. 1969. Glucose-6-phosphate dehydrogenase deficient red cells: resistance to infection by malarial parasites. Science 164:939
87. 80. MacDonald KS, Embree J, Njenga S, Nagelkerke NJD, Ndinya-Achola J, et al. 1998. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type I transmission. J. Infect. Dis. 177:551-56
88. 80a. Madsen HO, Garred P, Kurtzhals JA, Lamm LU, Ryder LP, et al. 1994. A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 40:37-44
89. 81. Magierowska M, Theodorou I, Debre P, Sanson F, Autran B, et al. 1999. Combined genotypes of CCR5, CCR2, SDF1, and HLA genes can predict the long-term nonprogressor status in human immunodeficiency virus-1-infected individuals. Blood 93:936-41
90. 82. Main J, McCarron B, Thomas HC. 1998. Treatment of chronic viral hepatitis. Antiviral Chem. Chemo. 9:449-60
91. 83. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, et al. 1998. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 282:1907-11
92. 84. Mcguire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. 1994. Variation in the TNF-α promoter region associated with susceptibility to cerebral malaria. Nature 371:508-11
93. 85. McGuire W, Knight JC, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D. 1999. Severe malaria anemia and cerebral malaria are associated with different tumor necrosis factor promoter alleles. J. Infect. Dis. 179:287-90
94. 86. Deleted in proof
95. 87. McNicholl JM, Cuenco K. 1998. Host genes and infectious diseases: HIV, other pathogens and a public health perspective. Am. J. Prev. Med. 16:141-54
96. 88. McNicholl JM, Downer M, Aidoo M, Hodge T, Udhayakumar V. Public health assessment of genetic susceptibility to infectious diseases: malaria, TB and HIV. In Genetics and Public Health: Translating Advances in Human Genetics Into Public Health Actions, ed. MJ Khoury. New York: Oxford Univ. Press. In press
97. 89. McNicholl JM, McDougal JS, KewalRamani VN, Smith D, Qari SH, Hodge T. 1998. Host gene polymorphism: effects on HIV entry, transmission and disease course. In Human Immunodeficiency Viruses: Biology, Immunology and Molecular Biology, ed. N Saksena, pp. 331-79. Genoa, Italy: Med. Syst.
98. 90. McNicholl JM, Smith DK, Qari SH, Hodge T. 1997. Host genes and HIV: the role of the chemokine receptor gene CCR5 and its allele (δ32 CCR5). Emerg. Infect. Dis. 3:261-71
99. 91. Meister GE, Roberts CG, Berzofsky JA, De Groot AS. 1995. Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine 13:581-91
100. 92. Milich DR. 1991. Immune response to hepatitis B virus proteins: relevance of the murine model. Semin. Liver Dis. 11:93-112
101. 93. Miller LH, Mason SJ, Clyde DF, McGinnis MH. 1976. The resistance factor to Plasmodium vivax in blacks: the Duffy-blood-group genotype, fyfy. N. Engl. J. Med. 295:303-4
102. 94. Monferran CG, Roth GA, Cumar FA. 1990. Inhibition of cholera toxin binding to membrane receptors by pig gastric mucin-derived glycopeptides: differential effect depending on the ABO blood group antigenic determinants. Infect. Immun. 58:3966-72
103. 95. Nagel RL, Roth EF. 1989. Malaria and red cell genetic defects. Blood 74:1213-21
104. 95a. National Center for Biotechnology Information, National Library of Medicine, http://www.ncbi.nlm.nih.gov
105. 96. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, Oostra BA, et al. 1996. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335:1941-49
106. 97. O'Brien SJ, Dean M. 1997. In search of AIDS-resistance genes. Sci. Am. 277:44-51
107. 98. O'Brien TR, Padian NS, Hodge T, Goedert JJ, O'Brien SJ, Carrington M. 1998. CCR5 genotype and sexual transmission of HIV. AIDS 12:444-45
108. 99. Pablos-Mendez A, Raviglione MC, Laszlo A. 1998. Global surveillance for antituberculosis-drug resistance 1994-1997. N. Engl. J. Med. 338:1641-49
109. 100. Pope J, Stevens A, Howson W, Bell D. 1998. The development of rheumatoid arthritis after recombinant hepatitis B vaccination. J. Rheumatol. 25:1687-93
110. 101. Qureshi ST, Skamene E, Malo D. 1999. Comparative genomics and host resistance against infectious diseases. Emerg. Infect. Dis. 5:36-47
111. 102. Rajalingam R, Mehra N, Jain R, Myneedu V, Pande J. 1996. Polymerase chain reaction based sequence-specific oligonucleotide hybridization of HLA class II antigens in pulmonary tuberculosis: relevance to chemotherapy and disease severity. J. Infect. Dis. 173:669-76
112. 103. Relman D. 1999. The search for unrecognized pathogens. Science 284:1308-10
113. 104. Rowe JA, Moulds JM, Newbold CI, Miller LH. 1997. P. falciparum rosetting mediated by parasite-variant erythrocyte membrane protein and complement-receptor 1. Nature 388:292-95
114. 104a. Roy S, Frodsham A, Saha B, Hazra SK, Mascie-Taylor CGN, Hill AVS. 1999. Association of vitamin D receptor genotype with leprosy type. J. Infect. Dis. 179: 187-91
115. 105. Ruwende C, Khoo SC, Snow RW, Yates SN, Kwiatkowski D, et al. 1995. Natural selection of hemi-and heterozygotes for G6PD deficiency in Africa by resistance to severe malaria. Nature 376:246-49
116. + cell count and rate of progression to AIDS following acute HIV-1 infection. AIDS 12:2107-13
117. 107. Deleted in pro of
118. 108. Salazar MH, Deulofeut H, Granja C, Deulofeut R, Yunis DE, et al. 1995. Normal HBsAg presentation and T-cell defect in the immune response to nonresponders. Immunogenetics 41:366-74
119. 109. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, et al. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-25
120. 110. Selvaraj P, Kannapiran M, Reetha A, Uma H, Xavier T, Narayanan P. 1997. HLA-DR2 phenotype and plasma lysozyme, beta-glucuronidase and acid phosphatase levels in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 1:265-69
121. 110a. Sherman IW. 1998. A brief history of malaria and discovery of the parasite's life cycle. In Malaria Parasite Biology, Pathogenesis, and Protection, ed. IW Sherman. Washington, DC: ASM Press, pp. 3-10
122. 111. Singh S, Mehra N, Dingley H, Pande J, Vaidya M. 1983. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. J. Infect. Dis. 148:676-81
123. 112. Sircar BK, Dutta P, De SP, Sikdar SN, Deb BC, Pal SC. 1981. ABO blood group distributions in diarrhoea cases including cholera in Calcutta. Ann. Hum. Biol. 8:289-91
124. 113. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, et al. 1997. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 277:959-65
125. 114. Stead WW. 1997. A molecular approach to tuberculosis control - an idea that might work. J. Infect. Dis. 176:547-48
126. 115. Stead WW, Senner JW, Reddick WT, Lofgren JP. 1990. Racial differences in susceptibility to infection by Mycobacterium tuberculosis. N. Engl. J. Med. 322:422-27
127. 116. Swerdlow DL, Mintz ED, Rodriguez M, Tejada E, Ocampo C, et al. 1994. Severe life-threatening cholera associated with blood group O in Peru: implications for the Latin American epidemic. J. Infect. Dis. 170:468-72
128. 117. Swerdlow DL, Ries AA. 1992. Cholera in the Americas: guidelines for the clinician. J. Am. Med. Assoc. 267:1495-99
129. 118. Tang J, Costello C, Keet IPM, Rivers C, Leblanc S, et al. 1999. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res. Hum. Retroviruses 15:317-24
130. 119. Teran-Escandon D, Teran-Ortiz L, Camarena-Olvera A, Gonzalez-Avila G, Vaca-Marin MA, et al. 1999. Human leukocyte antigen-associated susceptibility to pulmonary tuberculosis: molecular analysis of class II alleles by DNA amplification and oligonucleotide hybridization in Mexican patients. Chest 115:428-33
131. 120. Terrenato L, Shrestha S, Dixit KA, Luzzatto L, Modiano G, et al. 1988. Decreased malaria morbidity in the Tharu people compared to sympatric populations in Nepal. Ann. Trop. Med. Parasitol. 82:1-11
132. 121. Thomas HC, Foster GR, Sumiya M, McIntosh D, Jack DL, et al. 1996. Mutation of gene for mannose-binding protein associated with chronic hepatitis B viral infection. Lancet 348:1417-19
133. 122. Thursz MR. 1997. Host genetic factors influencing the outcome of hepatitis. J. Viral Hepatitis 4:215-20
134. 123. Thursz MR, Kwiatkowski D, Allsopp CEM, Greenwood BM, Thomas HC, Hill AVS. 1995. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 332:1065-69
135. 124. Thursz MR, Thomas HC, Greenwood BM, Hill AVS. 1997. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat. Genet. 17:11-1 2.
136. 125. Tiwari JL, Terasaki PI. 1985. Chronic active hepatitis and hepatitis B surface antigen. In HLA and Disease Associations, pp. 249-51. New York: Springer-Verl ag
137. 126. Tiwari JL, Terasaki PI. 1985. Carcinoma of the liver. In HLA and Disease Associations, pp. 285-87. New York: Springer-Verl ag
138. 126a. Tsuji K, Aizawa M, and Sasazuki T, eds. 1992. HLA 1991. Proc. Int. Histocompat. Workshop Conf., 11th, Yokahama, Japan. New York: Oxford Univ. Press. 1940 p p.
139. 127. Tuberculosis Chemotherapy Centre Madras. 1970. A controlled comparison of a twice-weekly and three once-weekly regimens in the initial treatment of pulmonary tuberculosis. Bull. World Health Organ. 43:143-206
140. 127a. UNAIDS and World Health Organization. 1999. AIDS Epidemic Update. http://www.unaids.org/hivaidsinfo/ documents.html
141. 128. Vidal S, Malo D, Vogan K, Skamene E, Gros P. 1993. Natural resistance to infection with intracellular parasites: isolation of a candidate for BCG. Cell 73: 469-86
142. 129. Vogel F, Motulsky AG. 1997. Human Genetics: Problems and Approaches. Berlin: Springer. 3rd ed. 581 pp.
143. 130. Deleted in proof
144. 131. Weatherall DJ, Clegg JB. 1981. The Thalassemia Syndromes. New York: Oxford, UK: Blackwell Sci. 3rd ed.
145. 132. Wilkinson R, Patel P, Llewelyn M, Hirsch C, Pasvol G, et al. 1999. Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1β on tuberculosis. J. Exp. Med. 189:1863-72
146. 133. Willcox M, Bjorkman A, Brohult J, Pehrson PO, Rombo L, Bengtsson E. 1983. A case-control study in northern Liberia of Plasmodium falciparum malaria in haemoglobin S and beta-thalassemia traits. Ann. Trop. Med. Parasitol. 77:239-46
147. 134. Williams TN, Maitland K, Bennett S, Ganczakowski M, Peto TE, et al. 1996. High incidence of malaria in alpha-thalassemic children. Nature 383:522-25
148. 135. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW 1997. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. USA 94:3195-99
149. 136. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, et al. 1998. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant: ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279:389-93
150. 137. World Health Organization. 1993. World malaria situation in 1991, part I. Wkly. Epidemiol. Rec. 68:245-52
151. 138. World Health Organization. 1998. Cholera in 1997. Wkly. Epidemiol. Rec. 27:201
152. 139. World Health Organization. 1998. Fifty facts from the World Health Report. Geneva: WHO. http://www.WHO.ORG/ whr/1998/factse.htm
153. 140. World Health Organization. 1998. Hepatitis B Fact Sheet WHO/204. http:// www.who.int/inf-fs/en/fact204.html
154. 141. Zavaglia C, Bortolon C, Ferrioloi G, Rho A, Mondazzi L, et al. 1996. HLA typing in chronic type B, D, and C hepatitis. J. Hepatol. 24:658-65